Apr 24, 2006
Aplab Ltd
APLAB LTD IS WINNESSING HIGERTR ACTIONA CROSS REVENUE STRREAMS. WE EXPECT THE STOCK TO BE OUTPERFROM OVER THE NEXT 3TO 6MONTH
OUTPERFROM:25%MORE
PERFROM:10 TO 15%
HOLD10% RETURN
UNDERFROM-5%
Gabrel Who Make Auto Mobile Parts good for long term buy
Wockhardt Ltd. soon touch RS 513 Soon
cipla will cross 274 tomarrow
SAYTAM computer will touch RS 900 Soon
PFIZER:
Pifzer Buys Rinat Neuroscience - Neurotech M&A Remains Hot
Posted by Zack Lynch
Pfizer is reportedly paying hundreds of millions of dollars for Rinat Neurosciences, a neuropharma company that has been developing therapies for pain, Alzheimer's and other neurological diseases. Terms of the deal weren't disclosed, but Pfizer has been rapidly adding to its pipeline by avidly buying up developers with promising therapies. Rinat has gained a reputation for its work on injectable protein-based therapies. The CEO of Rinat said that licensing talks turned to an offer of a buyout.
This is just another sign that a growing number of neurotech companies are going to establish their best valuation by an outright acquisition. With big pharma companies scrambling for new drugs and armed with billions of newly repatriated dollars, smaller biotech companies are looking like good investments. Add a somewhat sour market environment for IPOs and you have all the ingredients necessary for a big wave of acquisitions.
For a comprehensive analysis of neurotech M&A see the newly released Neurotechnology Industry 2006 Report.
Comments (1) + TrackBacks (0) Category: Neurotech Industry
COMMENTS
1. Kensai on April 8, 2006 11:05 AM writes...
Pharmaceutical companies have been quick to jump on the neurotechnology backwagon but I think we can still see more engineering [devices] companies addressing neurological maladies. Sky is the limit!
Stock Market trading involves risk and this website does not warrant or make any representations regarding the use or the results of the materials posted on this website or other sources in terms of their correctness, accuracy, reliability, profit, or otherwise. This website does not guarantee the accuracy or completeness of any information and is not responsible for any omissions. Trade in stock market is high risk& high return and We do not accept any financial and/or legal responsibility arising the use of the information.
by erectusplus at 8:37 PM |
0 Comments:
Post a Comment
<< Home